CN105579578A - 用于免疫调节的4-甲基伞形酮治疗 - Google Patents

用于免疫调节的4-甲基伞形酮治疗 Download PDF

Info

Publication number
CN105579578A
CN105579578A CN201480053371.4A CN201480053371A CN105579578A CN 105579578 A CN105579578 A CN 105579578A CN 201480053371 A CN201480053371 A CN 201480053371A CN 105579578 A CN105579578 A CN 105579578A
Authority
CN
China
Prior art keywords
compound
methylumbelliferone
autoimmune
composition
udp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480053371.4A
Other languages
English (en)
Chinese (zh)
Inventor
P·波利基
N·纳吉
T·怀特
H·F·库伊博斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Virginia Mason Medical Center
Leland Stanford Junior University
Original Assignee
Virginia Mason Medical Center
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virginia Mason Medical Center, Leland Stanford Junior University filed Critical Virginia Mason Medical Center
Publication of CN105579578A publication Critical patent/CN105579578A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201480053371.4A 2013-08-12 2014-08-12 用于免疫调节的4-甲基伞形酮治疗 Pending CN105579578A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361865084P 2013-08-12 2013-08-12
US61/865,084 2013-08-12
PCT/US2014/050770 WO2015023691A2 (en) 2013-08-12 2014-08-12 4-methylumbelliferone treatment for immune modulation

Publications (1)

Publication Number Publication Date
CN105579578A true CN105579578A (zh) 2016-05-11

Family

ID=52468796

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480053371.4A Pending CN105579578A (zh) 2013-08-12 2014-08-12 用于免疫调节的4-甲基伞形酮治疗

Country Status (5)

Country Link
US (2) US10285976B2 (https=)
EP (1) EP3033416A4 (https=)
JP (2) JP2016530265A (https=)
CN (1) CN105579578A (https=)
WO (1) WO2015023691A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114425050A (zh) * 2022-02-09 2022-05-03 深圳大学 一种4-甲基伞形酮在制备抗过敏药物中的应用

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9833614B1 (en) 2012-06-22 2017-12-05 Nevro Corp. Autonomic nervous system control via high frequency spinal cord modulation, and associated systems and methods
AU2016270373A1 (en) 2015-06-05 2018-01-04 Vertex Pharmaceuticals Incorporated Triazoles for the treatment of demyelinating diseases
WO2017213268A1 (ja) * 2016-06-10 2017-12-14 国立大学法人東北大学 インスリン分泌促進剤又はインスリン抵抗性改善剤
WO2018106646A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Aminotriazoles for the treatment of demyelinating diseases
WO2018106641A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Pyrazoles for the treatment of demyelinating diseases
WO2018106643A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Heterocyclic azoles for the treatment of demyelinating diseases
US10370400B2 (en) * 2017-01-13 2019-08-06 The Board Of Trustees Of The Leland Stanford Junior University 4-methylumbelliferone derivatives for treatment for immune modulation
US11278518B2 (en) 2017-01-13 2022-03-22 The Board Of Trustees Of The Leland Stanford Junior University Methods of treatment using 4-methylumbelliferone and derivatives thereof
WO2019165319A1 (en) * 2018-02-23 2019-08-29 The Board Of Trustees Of The Leland Stanford Junior University The use of 4-methylumbelliferone to prevent immune rejection in cases of tissue transplantation
WO2019191601A1 (en) * 2018-03-29 2019-10-03 Nevro Corp. Therapeutic modulation to treat blood glucose abnormalities, including type 2 diabetes, and/or reduce hba1c levels, and associated systems and methods
JP2022514672A (ja) * 2018-12-20 2022-02-14 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー ヒアルロナン合成阻害のための４－メチルウンベリフェリルグルクロニド
JP2022554230A (ja) * 2019-10-25 2022-12-28 クウォク ジェシカ 神経系の状態の処置
WO2021203051A1 (en) * 2020-04-03 2021-10-07 Standard Of Care Corporation Aerosolized hyaluronidase and/or 4-methylumbelliferone compositions and methods of using same to treat respiratory diseases or disorders

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004082610A2 (en) * 2003-03-14 2004-09-30 Brigham And Women's Hospital, Inc. Modulation of hyaluronan and cd44 interaction and uses thereof in treating disorders
CN102846598A (zh) * 2012-08-03 2013-01-02 广州康臣药物研究有限公司 香豆素在制备AGEs形成抑制剂中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4451933B2 (ja) 1996-12-27 2010-04-14 住友化学株式会社 遺伝子操作による植物へのｐｐｏ阻害性除草剤耐性付与法
GB9722600D0 (en) * 1997-10-24 1997-12-24 Bio Monde Holdings Internation Pharmaceutical compositon
JP2004517030A (ja) * 1999-05-24 2004-06-10 アバロン バイオサイエンシーズ， インコーポレイテッド グリコシルトランスフェラーゼインヒビター
DE60037113T2 (de) 1999-05-24 2008-09-18 Abaron Biosciences, Inc., Del Mar Glycosyltransferase inhibitoren
GB0205022D0 (en) * 2002-03-04 2002-04-17 Univ Cambridge Tech Materials and methods for the treatment of cns damage
CA2486302A1 (en) 2002-05-17 2003-11-27 Faust Pharmaceuticals Methods for the prevention and/or the treatment of neurological disorders
AU2004262494B2 (en) * 2003-07-29 2009-01-15 Universitaetsklinikum Muenster Means and methods for treating a disease which is associated with an excess transport of hyaluronan across a lipid bilayer
WO2011057034A2 (en) 2009-11-05 2011-05-12 Sloan Kettering Institute For Cancer Research Catenae: serosal cancer stem cells
WO2012012300A2 (en) * 2010-07-20 2012-01-26 Halozyme, Inc. Adverse side-effects associated with administration of an anti-hyaluronan agent and methods for ameliorating or preventing the side-effects
CN108686203A (zh) * 2012-04-04 2018-10-23 哈洛齐梅公司 使用抗透明质酸剂和肿瘤靶向紫杉烷的组合疗法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004082610A2 (en) * 2003-03-14 2004-09-30 Brigham And Women's Hospital, Inc. Modulation of hyaluronan and cd44 interaction and uses thereof in treating disorders
CN102846598A (zh) * 2012-08-03 2013-01-02 广州康臣药物研究有限公司 香豆素在制备AGEs形成抑制剂中的应用

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ANNE KULTTI ET AL.: "4-Methylumbelliferone inhibits hyaluronan synthesis by depletion of cellular UDP-glucuronic acid and downregulation of hyaluronan synthase 2 and 3", 《EXPERIMENTAL CELL RESEARCH》 *
ANNELE SAINIO ET AL.: "Hyperglycemic conditions modulate connective tissue reorganization by human vascular smooth muscle cells through stimulation of hyaluronan synthesis", 《GLYCOBIOLOGY》 *
L. W. LAWRENCE WOO ET AL.: "Active Site Directed Inhibition of Estrone Sulfatase by Nonsteroidal Coumarin Sulfamates", 《J. MED. CHEM.》 *
YUTAKA YOSHIOKA ET AL.: "Suppression of Hyaluronan Synthesis Alleviates Inflammatory Responses in Murine Arthritis and in Human Rheumatoid Synovial Fibroblasts", 《ARTHRITIS & RHEUMATISM》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114425050A (zh) * 2022-02-09 2022-05-03 深圳大学 一种4-甲基伞形酮在制备抗过敏药物中的应用

Also Published As

Publication number Publication date
JP2019135262A (ja) 2019-08-15
WO2015023691A3 (en) 2015-04-09
WO2015023691A2 (en) 2015-02-19
EP3033416A4 (en) 2017-02-08
EP3033416A2 (en) 2016-06-22
US10285976B2 (en) 2019-05-14
JP2016530265A (ja) 2016-09-29
US20160184262A1 (en) 2016-06-30
US20200101042A1 (en) 2020-04-02

Similar Documents

Publication Publication Date Title
US20200101042A1 (en) 4-methylumbelliferone treatment for immune modulation
Sciorati et al. Cell death, clearance and immunity in the skeletal muscle
KR100294060B1 (ko) 면역억제제로서히알루론산을이용하는방법
US8454967B2 (en) Compositions and methods for modulating the immune system
AU602154B2 (en) Improvements in or relating to organic compounds
JPH06507635A (ja) 病理学的過程の予防および／または治療用組成物
ES2810227T3 (es) Biomarcadores de diabetes
Liao et al. Low molecular weight polysialic acid prevents lipopolysaccharide‐induced inflammatory dopaminergic neurodegeneration in humanized SIGLEC11 transgenic mice
Naseri et al. Targeting Glycoproteins as a therapeutic strategy for diabetes mellitus and its complications
Buschard What causes type 1 diabetes? Lessons from animal models
JP4804626B2 (ja) 免疫レギュレータ
CN1794999B (zh) 神经损伤治疗剂
US10370400B2 (en) 4-methylumbelliferone derivatives for treatment for immune modulation
Liu et al. Upregulation of Nogo receptor expression induces apoptosis of retinal ganglion cells in diabetic rats
EP2086553A1 (en) Inhibition of degradation of extracellular matrix
EP2802342B1 (en) Peptide and uses thereof
Colamatteo et al. Obesity and Autoimmunity Epidemic: The Role of Immunometabolism
WO2005025502A2 (en) A method for treating or inhibiting the effects of injuries or diseases that result in neuronal degeneration
KR20220010552A (ko) 항-abeta 백신 요법
EP1572230A1 (en) Placental alkaline phosphatase to control diabetes
US20220088010A1 (en) Co-Administration of inhibitors to produce insulin producing gut cells
JP2022511974A (ja) 免疫抑制のための組成物および方法
AU2014306775A1 (en) 4-methylumbelliferone treatment for immune modulation
AU2018315052B2 (en) Type 1 diabetes therapy
CA3008182A1 (en) Non-agglomerating bioconjugates of amylin and amylin-mimetic compounds, compositions comprising the same, and making and use thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20160511

WD01 Invention patent application deemed withdrawn after publication